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ber	of	 organ	 failures	 (area	under‐the‐curve	 [AUC],	 0.76).	 In	 the	 validation	 set,	 the	
LacOF	model	discriminative	ability	(AUC,	0.85)	outperformed	the	CLIF‐SOFA	(AUC,	
0.79),	Chronic	Liver	Failure	Consortium	Acute‐on‐Chronic	Liver	Failure	(AUC,	0.73),	





help	 to	 better	 stratify	 the	 risk	 of	 ICU	mortality	 and	 thus	 optimize	 organ	 support	
strategies.
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1  | INTRODUC TION
Patients	 with	 cirrhosis	 and	 organ	 failures	 have	 been	 defined	 as	
having	 acute‐on‐chronic	 liver	 failure	 (ACLF).1	 This	 clinical	 entity	
portends	significantly	higher	overall	mortality	than	acutely	decom‐
pensated	 cirrhosis.2	 Despite	 the	 nature	 of	 the	 precipitant	 event	
associated	 with	 the	 acute	 deterioration	 (eg	 infection,	 bleeding	 or	














Existing	 prognostic	 tools	 for	 patients	with	 cirrhosis	 not	 nec‐
essarily	 admitted	 to	 the	 ICU	 (eg	 Chronic	 Liver	 Failure‐C	 ACLF	
[CLIF‐C	 ACLF]	 and	 Model	 for	 End‐stage	 Liver	 Disease	 [MELD]	
scores)	or	for	the	general	critically	ill	patients	(eg	Sequential	Organ	









Furthermore,	we	 sought	 to	develop	 an	 alternative	prognostic	 tool	
for	this	specific	setting.
2  | MATERIAL S AND METHODS





and	 University	 of	 Alberta	 Hospital	 (Edmonton,	 Canada)	 from	 1	
March	 2010	 to	 30	 September	 2013	 (n	=	170).	 A	 validation	 set	 in‐
cluded	consecutive	patients	with	cirrhosis	and	organ	failures	admit‐
ted	 to	 the	 ICU	of	 another	 LT	 centre:	 Vancouver	General	Hospital	
(Vancouver,	Canada)	from	1	June	2000	to	31	March	2011	(n	=	237).
Patients	 were	 included	 if	 fulfilling	 the	 following	 criteria:	 age	
≥18	years;	 diagnosed	 with	 cirrhosis	 and	 organ	 failures	 (defined	
by	 Chronic	 Liver	 Failure	 Sequential	 Organ	 Failure	 Assessment	
[CLIF‐SOFA]	score);	and	on	first	admission	to	ICU	during	the	inclu‐
sion	period	at	each	study	site.	Exclusion	criteria	were:	diagnosis	of	













waived	 the	need	 for	 individual	 informed	consent.	All	 study	proce‐
dures	 followed	 the	 principles	 of	 the	Declaration	 of	Helsinki.8	 The	
reporting	of	this	study	followed	the	Strengthening	the	Reporting	of	
Observational	Studies	in	Epidemiology	(STROBE)	guideline.9
2.2 | Definitions, exposures and endpoints
Cirrhosis	was	defined	as	a	bridging	fibrosis	on	previous	liver	biopsy	
or	 a	 composite	 of	 clinical	 signs	 and	 findings	 provided	 by	 labora‐
tory	 tests,	 endoscopy	 and	 radiologic	 imaging.1	Organ	 failures	 and	
ACLF	 criteria	were	 defined	 based	 on	 the	CLIF‐SOFA	 score	 as	 per	
European	Foundation	for	 the	Study	of	Chronic	Liver	Failure	 (CLIF)	
Consortium.2
The	ACLF	 grading	 system	 ranks	 patients	with	 ACLF	 in	 one	 of	
three	grades	based	on	the	number	of	organ	failures	according	to	the	
CLIF‐SOFA	score:	grade	1	if	(a)	single	kidney	failure	(serum	creatinine	















prognostic	 tools	 and	 showed	 an	 overall	 good	
performance.




Severity	 of	 illness	 systems	 considered	 on	 admission	 to	 ICU	
was:	CLIF‐SOFA,	CLIF‐C	ACLF,	CLIF‐C	ACLF	Lac,	APACHEII	and	
MELD	scores.	The	CLIF‐SOFA	score	 is	 a	validated	adaptation	of	
the	 classical	 SOFA	 to	 assess	 the	 severity	 of	 disease	 in	 patients	
with	 cirrhosis	derived	by	 the	CLIF	Consortium.	 It	 comprises	 the	
grading	 of	 six	 different	 systems	 of	 organs	 (ranging	 each	 from	0	
[least	severe]	to	4	[most	severe]	and	overall	from	0	to	24):	brain,	
cardiovascular	system,	lungs,	kidneys,	liver	and	coagulation.2	The	
CLIF‐C	 ACLF	 score	 prognosticates	 28‐day	 mortality	 in	 patients	
with	 ACLF	 by	 adding	 the	 number	 of	 organ	 failures,	 defined	 by	
the	CLIF‐SOFA	 score,	 to	 age	 and	white	 blood	 cells’	 count.7	 The	
CLIF‐C	ACLF	Lac	score	was	recently	developed	to	prognosticate	
28‐day	mortality	 in	patients	with	 cirrhosis	 in	 the	 ICU	by	adding	
lactate	 level	 on	 admission	 to	 ICU	 to	 the	 CLIF‐C	 ACLF	 score.10 
The	APACHEII	score	has	been	widely	used	for	several	decades	to	






portal	 hypertension	 who	 underwent	 a	 transjugular	 intrahepatic	









that	 occurred	 within	 6‐months	 following	 admission	 to	 ICU	 in	 the	
training	 set.	 Furthermore,	 the	 sensitivity	 analysis	 performed,	 ex‐
cluding	 patients	who	were	 transplanted	 during	 the	 follow‐up,	 did	
not	show	any	 impact	of	LT	status	 in	 this	study	of	 the	associations	
with	ICU	mortality.	The	secondary	endpoints	defined	were	all‐cause	




dian	 (interquartile	 range	 [IQR])	and	 frequency	 (percentage	 [%])	 re‐
spectively.	Univariate	comparisons	were	done	using	Mann‐Whitney	
and	 chi‐square	 tests	where	 appropriate.	Multivariate	 analysis	was	
performed	with	 logistic	 regression.	 Survival	 analysis	 used	Kaplan‐
Meier	curves	with	comparisons	being	done	with	 the	Breslow	test.	
Overall	missing	data	on	admission	to	ICU	were	0.5%.
The	 development	 of	 the	 new	 predictive	 model	 (Lisbon	 and	









ability	 to	predict	an	absolute	 likelihood	of	 ICU	mortality	based	on	
how	closely	 the	actual	 and	predicted	outcomes	agree)	by	plotting	
observed	 against	 predicted	 ICU	 mortality	 rates;	 and	 overall	 per‐
formance	with	R2	and	Brier	score	 (higher	R2	and	 lower	Brier	score	
indicate	better	 performance).13	 Internal	 validation	was	done	using	
bootstrapping	 (1000	 samples).	 External	 validation	 was	 performed	
using	another	cohort	from	a	different	region	(Vancouver).
Statistical	 significance	 was	 defined	 as	 P	<	0.05	 (two‐tailed).	
Statistical	 analysis	was	 performed	 using	 IBM	 SPSS	 Statistics,	 ver‐
sion	20	(IBM	Corp,	North	Castle,	NY),	MedCalc	Statistical	Software,	
version	 16.4.3	 (MedCalc	 Software	 bvba,	 Ostend,	 Belgium)	 and	 R,	
with	 rms	 and	 predictABEL	 packages	 (R	 Foundation	 for	 Statistical	
Computing,	Vienna,	Austria).
3  | RESULTS
3.1 | Baseline characteristics and outcomes for the 
training set
A	total	of	240	patients	(70	from	Curry	Cabral	Hospital	and	170	from	












During	 the	 index	 ICU	 and	 hospital	 stays,	 94	 (39.2%)	 and	 131	
(54.6%)	 patients	 died	 respectively.	 Overall	 cumulative	 survival	 is	








μL),	 INR	 (2.3	 vs	 1.7),	 bilirubin	 (7.3	 vs	 3.6	mg/dL),	 lactate	 (4.4	 vs	
2.5	mmol/L),	 number	 of	 organ	 failures	 (3	 vs	 2),	 need	 for	 renal	 re‐
placement	therapy	(30.9%	vs	17.8%),	need	for	vasopressors	(73.4%	
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TA B L E  1  Baseline	characteristics	stratified	by	mortality	within	the	ICU	stay	in	the	training	set
 Overall (n = 240) Deceased in ICU (n = 94) Alive in ICU (n = 146) Pa 
Age 57	(50‐63) 59	(52‐64) 56	(49‐62) 0.017
Sex	(male) 168	(70.0%) 67	(71.3%) 101	(69.2%) 0.73
Aetiology
Alcohol 100	(41.7%) 42	(44.7%) 58	(39.7%) 0.29
HCV 29	(12.1%) 15	(16.0%) 14	(9.6%)
Alcohol	+	HCV 51	(21.2%) 17	(18.1%) 34	(23.3%)
Other 60	(25.0%) 20	(21.3%) 40	(27.4%)
HCC 7	(2.9%) 4	(4.3%) 3	(2.1%) 0.33
Ascites	(n	=	237) 162	(68.4%) 70	(75.3%) 92	(63.9%) 0.067
Precipitant	event
Sepsis 82	(34.2%) 37	(39.4%) 45	(30.8%) 0.58
Bleeding 32	(13.3%) 12	(12.8%) 20	(13.7%)
Other 100	(41.7%) 35	(37.2%) 65	(44.5%)
Unknown 26	(10.8%) 10	(10.6%) 16	(11.0%)
Laboratory
Haemoglobin	(g/L) 87	(76‐101) 86	(74‐100) 89	(77‐101) 0.40
Leucocytes	(103/μL) 11.0	(7.8‐15.9) 10.4	(6.5‐15.7) 11.2	(8.3‐16.0) 0.48
Platelets	(103/μL)	(n	=	239) 78	(46‐121) 63	(39‐107) 88	(57‐136) 0.001
INR 1.9	(1.6‐2.5) 2.3	(1.8‐2.9) 1.7	(1.5‐2.2) <0.001
Bilirubin	(mg/dL) 4.5	(2.2‐12.6) 7.3	(3.3‐19.2) 3.6	(2.0‐8.7) 0.013
Albumin	(g/dL)	(n	=	205) 28.0	(22.0‐33.0) 26.4	(21.0‐32.8) 29.0	(22.9‐33.3) 0.54
Creatinine	(mg/dL) 1.42	(0.90‐2.60) 1.79	(1.13‐2.72) 1.17	(0.78‐2.19) 0.67
Sodium	(mmol/L) 135	(131‐141) 135	(129‐141) 136	(132‐140) 0.70
Lactate	(mmol/L)	(n	=	227) 3.2	(1.9‐6.5) 4.4	(3.0‐10.3) 2.5	(1.6‐4.3) <0.001
Organ	failuresb  3	(2‐4) 3	(2‐4) 2	(1‐3) <0.001
Liver 61	(25.4%) 33	(35.1%) 28	(19.2%) 0.006
Kidneys 100	(41.7%) 52	(55.3%) 48	(32.9%) 0.001
Brain 155	(64.6%) 64	(68.1%) 91	(62.3%) 0.36
Coagulation 67	(27.9%) 42	(44.7%) 25	(17.1%) <0.001
Circulation 156	(65.0%) 69	(73.4%) 87	(59.6%) 0.030
Lungs 105	(43.8%) 49	(52.1%) 56	(38.4%) 0.036
Organ	support
RRT 55	(22.9%) 29	(30.9%) 26	(17.8%) 0.020
Vasopressors 156	(65.0%) 69	(73.4%) 87	(59.6%) 0.030
IMV 171	(71.2%) 69	(73.4%) 102	(69.9%) 0.55
PF	ratio	(mmHg) 215	(144‐307) 183	(113‐277) 226	(159‐315) 0.084
ACLF	gradeb 
No	ACLF 34	(14.2%) 3	(3.2%) 31	(21.2%) <0.001
1 21	(8.8%) 3	(3.2%) 18	(12.3%)
2 58	(24.2%) 18	(19.1%) 40	(27.4%)
3 127	(52.9%) 70	(74.5%) 57	(39.0%)
CLIF‐SOFA 14	(11‐17) 15	(14‐18) 13	(10‐16) <0.001
CLIF‐C	ACLF 58	(51‐65) 63	(57‐69) 55	(49‐62) <0.001
CLIF‐C	ACLF	Lac 61	(52‐72) 69	(60‐78) 55	(48‐65) <0.001
APACHEII 23	(19‐29) 27	(21‐32) 22	(18‐26) <0.001
(Continues)






and	 S3	 respectively.	 Cumulative	 survival	 stratified	 by	 lactate	 and	








3.2 | Development of the new predictive model
To	 start	 developing	 the	 new	 predictive	 model	 for	 ICU	 mortality,	
we	initially	included	the	following	variables:	age,	sex,	ascites,	plate‐
lets,	INR,	bilirubin,	lactate,	number	of	organ	failures,	need	for	renal	
replacement	 therapy,	 need	 for	 vasopressors	 and	 arterial	 oxygen	
partial	pressure/oxygen	 inspiration	fraction	ratio.	Through	a	back‐
ward	 stepwise	 elimination	 process,	 the	 best	 predictive	model	 for	
ICU	mortality	derived	comprised	 the	 following	variables	 (Table	2):	
lactate	(adjusted	odds	ratio	[aOR]	=	1.08)	and	the	number	of	organ	
failures	(aOR	=	1.77)	(P	<	0.04	for	both).	The	new	predictive	model	
(lactate	 and	 organ	 failures	 predictive	 model	 [LacOF])	 performed	
reasonably	well	in	the	training	set	with	an	AUC	of	0.76,	a	R2	of	0.23	
and	a	Brier	score	of	0.20	(Figure	1A).	Overall,	68%	of	the	patients	
were	 correctly	 classified.	The	 logistic	 regression	equation	derived	
















To	account	 for	 the	possible	effect	of	LT	 in	 the	association	of	
lactate	 and	 the	 number	 of	 organ	 failures	 on	 admission	 to	 ICU	
with	 ICU	 mortality,	 we	 performed	 a	 sensitivity	 analysis	 exclud‐




3.3 | External validation of the new predictive 
model (validation set)
A	total	of	237	patients	from	Vancouver	General	Hospital	fulfilled	




failures	 (2	vs	3;	P	=	0.25).	Furthermore,	 the	 two	sets	had	 similar	
proportion	of	ACLF	grade	3	 (46.8%	vs	52.9%)	and	median	CLIF‐
SOFA	(14	vs	14),	CLIF‐C	ACLF	(58	vs	58),	CLIF‐C	ACLF	Lac	(61	vs	
62),	 APACHEII	 (23	 vs	 23;	P	=	0.77)	 and	MELD	 scores	 (27	 vs	 27;	
P	>	0.05	for	all).
TA B L E  2  LacOF	model	to	predict	mortality	within	intensive	care	
unit	stay
 OR (95% CI) aOR (95% CI)a  Pb 


















 Overall (n = 240) Deceased in ICU (n = 94) Alive in ICU (n = 146) Pa 
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(P	=	0.043)	 respectively.	 Five	 (2.1%)	 patients	 were	 transplanted	
during	the	follow‐up	and	none	of	these	died	within	the	index	hospi‐
tal	stay.	Median	(IQR)	length	of	ICU	and	hospital	stays	were	4	(2‐9)	
and	13	 (5‐25)	days	 respectively.	Median	 (IQR)	 length	of	 follow‐up	
was	9	(2‐19)	days.
The	 overall	 prognostic	 performance	 of	 the	 LacOF	 model	
for	 ICU	mortality	was	better	 in	 the	validation	 set	 in	 comparison	
to	 the	 training	 set	with	 an	AUC	of	0.85	vs	0.76,	 a	R2	 of	0.32	vs	
0.23	 and	 a	Brier	 score	of	0.19	vs	0.20	 respectively	 (Table	3	 and	
Figure	1C).	Overall,	79%	of	the	patients	were	correctly	classified.	
In	 fact,	 the	 LacOF	model	 discriminative	 ability	 in	 the	 validation	
set	outperformed	several	other	prognostic	systems,	including	the	










Using	 a	 reasonably	 large	 international	 multicentre	 cohort	 of	 pa‐
tients	with	ACLF	admitted	 to	 ICU	 (training	 set),	we	 compared	 the	

















cohort	 of	 84	 critically	 ill	 patients	with	 cirrhosis	 and	 demonstrated	
that	 lactate	 on	 admission	 to	 ICU	was	 significantly	 associated	with	
ICU	mortality	with	an	aOR	of	1.89.15	Finally,	Edmark	et	al.	assembled	





F I G U R E  2  Predicted	probability	of	intensive	care	unit	(ICU)	
mortality	based	on	lactate	(mmol/L)	and	the	number	of	organ	
failures	on	admission	to	ICU
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While	 the	number	of	organ	 failures	present	on	admission	 to	
ICU	 seems	 to	 be	 important	 for	 patients’	 short‐term	 prognosis,	
the	type	of	organs	failing	may	 impact	differently	the	overall	se‐








the	 ICU	 stay	 (OR	 [95%	 confidence	 interval]	=	0.06	 [0.01‐0.48]).	
This	 may	 help	 explain	 why	 cerebral	 failure	 was	 not	 associated	
with	 ICU	mortality	 in	 our	 training	 set.	 Furthermore,	 this	 ratio‐







validation	 set	 (39.2%	vs	51.1%;	P	=	0.009).	Furthermore,	while	 the	
APACHEII	discriminative	ability	for	the	training	and	validation	sets	
was	 similar	 (AUC	of	0.73	vs	0.74),	 its	 calibration	was	poor	 for	 the	
training	set	(Figure	1B)	but	good	for	the	validation	set	(Figure	1D).
As	the	validation	set	was	an	older	cohort	than	the	training	set,	
this	 difference	 in	 the	 APACHEII	 calibration	 was	 likely	 because	 of	
Model
ICU mortality Hospital mortality
AUC (95% CI) Pa  AUC (95% CI) Pa 
Training	set
LacOF 0.76	(0.70‐0.82) NA 0.77	(0.71‐0.83) NA
CLIF‐SOFA 0.70	(0.63‐0.77) 0.047 0.71	(0.64‐0.78) 0.014
CLIF‐C	ACLF 0.71	(0.65‐0.76) 0.10 0.73	(0.67‐0.79) 0.08
CLIF‐C	ACLF	Lac 0.76	(0.70‐0.82) 0.98 0.76	(0.70‐0.83) 0.62
APACHEII 0.73	(0.66‐0.81) 0.61 0.71	(0.64‐0.79) 0.036
MELD 0.70	(0.64‐0.77) 0.13 0.73	(0.66‐0.79) 0.21
Validation	set
LacOF 0.85	(0.80‐0.90) NA 0.84	(0.78‐0.89) NA
CLIF‐SOFA 0.79	(0.73‐0.84) 0.042 0.81	(0.76‐0.86) 0.54
CLIF‐C	ACLF 0.73	(0.67‐0.79) 0.004 0.76	(0.70‐0.81) 0.04
CLIF‐C	ACLF	Lac 0.82	(0.77‐0.88) 0.17 0.83	(0.78‐0.89) 0.73
APACHEII 0.74	(0.68‐0.79) 0.003 0.71	(0.64‐0.76) 0.001
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the	expected	decrease	in	ICU	mortality	from	the	2000‐2011	period	
(validation	 set)	 to	 the	 2010‐2016	 period	 (training	 set).	 Therefore,	
this	 ICU	 mortality	 discrepancy	 between	 the	 two	 sets	 was	 likely	
related	 to	 the	 overall	 improvements	 in	 critical	 care	medicine	 over	
the	 past	 decades,	 including	 the	management	 of	 patients	with	 cir‐
rhosis.	In	fact,	McPhail	et	al.	used	a	retrospective	cohort	of	patients	





Despite	 this	 limitation	 of	 the	 validation	 set,	 the	 LacOF	model	
overall	prognostic	performance	was	good	in	a	substantially	different	























this	 was	 a	 retrospective	 study,	 thus	 may	 have	 been	 prone	 to	
TA B L E  4  Baseline	characteristics	in	the	validation	set















































 Overall (n = 237)
MELD 27	(20‐35)
ICU,	intensive	care	unit;	HCV,	hepatitis	C	virus;	HCC,	hepatocellular	car‐
cinoma;	 INR,	 international	 normalized	 ratio;	 RRT,	 renal	 replacement	
therapy;	 IMV,	 tracheal	 intubation	with	or	without	 invasive	mechanical	
ventilation;	PF	ratio,	arterial	oxygen	partial	pressure	and	oxygen	inspira‐
tion	 fraction	 ratio;	 ACLF,	 acute‐on‐chronic	 liver	 failure;	 CLIF‐SOFA,	
Chronic	 Liver	 Failure	 –	 Sequential	 Organ	 Failure	 Assessment	 score;	





TA B L E 4 (Continued)
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selection	 bias.	 However,	 the	 international	multicentre	 character,	
the	reasonably	large	sample	size	(similar	to	studies	previously	re‐
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